Ocrevus 300 mg Concentrate solution for infusion
PDF Leaflet Revision Date: 20 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsing and primary progressive multiple sclerosis.
Dosage (summary)
Initial: 600 mg IV (2x300 mg, 2 weeks apart); Subsequent: 600 mg IV every 6 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use contraception during treatment and for 6 months after.
Contraindications
- Hypersensitivity to ocrelizumab
- Life-threatening infusion reactions
- Active hepatitis B/C
- Active infections
- Live vaccines
Common side effects
- Infusion-related reactions
- Upper respiratory tract infections
- Nasopharyngitis
Counselling Points
- Premedicate with steroids and antihistamines before infusion
- Monitor for infusion-related reactions
- Avoid live vaccines during and post-treatment
Serious warnings
- Risk of PML
- Hepatitis B reactivation
- Serious infections
Important Disclaimer
The Ocrevus 300 mg Concentrate solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
